gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · HAEHealthcareSurgical Instruments

Haemonetics Corporation (HAE)

$127.42+5.94%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$126.95▲ 152.54% in range
Nov 3, 2025Low $50.27 · High $126.95Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Haemonetics closed at $127.42 on Nov 4, up 5.94% — matching its 52-week closing high. Volume of 982.0K shares was 1.26× its 20-day average (above normal).

Split-adjusted performance: +23.1% over one month, +141.9% over six months, +153.5% over one year.

In the quarter ended Jun 27, 2026, revenue was $339.38M, up 5.6% from a year earlier, with a net margin of 9.7%.

Short interest was 3.4M shares at the Oct 15 settlement, up 12.8% from the prior report (7.7% of float, 3.9 days to cover).

Market cap$5.80B45.5M shares
Revenue · quarter$339.4M+5.6% YoY
Diluted EPS$0.72+2.9% YoY
P/E · TTM60.2×P/S 4.3×
Net margin9.7%Gross 59.8%
Dividend yieldNone
52-week range50.27 – 127.420.0% from high
Volume982.0K1.26× 20-day avg
Volatility · 60d49.7%Annualised
Short % of float7.7%3.9 days to cover
Net cash-$950.8MCash $223.4M
Next earnings—Not scheduled
Split-adjusted performance
1W +7.7%1M +23.1%3M +49.9%6M +141.9%YTD +59.0%1Y +153.5%3Y +50.0%5Y +86.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum98
Revenue growth39
Net margin76
Value (low P/E)20
Size86

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short3.4M+12.8% vs prior
Days to cover3.9Settled Oct 15
% of float7.7%
Short vol. 10d49.9%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
HAEHaemonetics$127.42+5.94%+141.9%+5.6%9.7%60.2$5.80B
MMSIMerit Medical Systems$90.63+7.69%+47.1%+8.4%10.2%33.9$5.43BCompare
MMEDMiniMed Group$19.29+2.33%——0.0%—$5.43BCompare
TFXTeleflex Incorporated$149.87+7.09%+21.6%+28.9%17.5%—$6.35BCompare
HTFLHeartflow$56.57+3.99%+86.8%—−24.6%—$4.92BCompare
IRTCiRhythm Holdings$134.00+6.04%+13.8%+20.1%−0.2%—$4.42BCompare
ICUIICU Medical$172.62+6.67%+44.3%+0.5%3.5%143.5$4.32BCompare
PLSEPulse Biosciences, Inc Common Stock (DE)$57.06+9.31%+197.0%—−5681.3%—$4.07BCompare
ATRCAtriCure$65.53+8.48%+134.0%+12.8%5.8%315.9$3.33BCompare

News about Haemonetics

All news →
GEHC vs. HAE: Which Stock Is the Better Value Option?Zacks Investment Research · 6d agoNeutralAll You Need to Know About Haemonetics (HAE) Rating Upgrade to BuyZacks Investment Research · Oct 27, 2026▲ PositiveHaemonetics Gains 149.3% in a Year: What's Driving the Rally?Zacks Investment Research · Oct 16, 2026▲ PositiveWhy Haemonetics (HAE) is a Top Momentum Stock for the Long-TermZacks Investment Research · Oct 13, 2026▲ PositiveStrength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?Zacks Investment Research · Oct 9, 2026Neutral

Quick answers

What does Haemonetics do?
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital.
What is HAE's market cap?
$5.80B, based on the Nov 4 close of $127.42.
What is HAE's P/E ratio?
60.2× trailing-twelve-month earnings of $96.29M.
Does Haemonetics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of HAE is sold short?
3.4M shares, 7.7% of float, as of Oct 15, 2026.
What sector is HAE in?
Healthcare, in the Surgical Instruments industry.

About Haemonetics

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.

HQ: Boston, MA3,009 employeesListed May 9, 1991haemonetics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology